A Phase 2 interventional study of Pozelimab and Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2021, is one of 3 in phase 2, and was the 3rd registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Italy and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, Korea, Republic of, United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Colombia and 18 more countries
Ages 18+
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2021.
This study's enrollment of 24 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 24 across the 9 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and tolerability of 2 dosing regimens of pozelimab and cemdisiran combination therapy during the open-label treatment period (OLTP)
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pozelimab · Drug: Cemdisiran
Drug: Pozelimab · Drug: Cemdisiran
Administered Sub-cutaneous (SC) per protocol
Also known as: REGN3918
Administered SC per protocol
Also known as: ALN-CC5
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Open Label Treatment Period (OLTP)
Time frame: Through Week 28
Percent Change of Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period
OLTP Pre-treatment (mean of LDH values prior to combination dosing); End-of-treatment (mean of LDH value at week 24- through week 28); percentage of change in Upper Limit of Normal (xULN).
Time frame: End of treatment period, approximately 28 Weeks
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1) Through Week 28
OLTP Adequate control of hemolysis is defined as LDH values ≤1.5 × Upper limit of normal (ULN) from baseline (day 1) to week 28
Time frame: Baseline (Day 1) through Week 28
Percentage of Participants Maintaining Adequate Control of Hemolysis From Week 4 Through Week 28
OLTP
Time frame: Week 4 through Week 28
Percentage of Participants With Adequate Control of Hemolysis at Each Visit Day 1 Through Week 28
OLTP; Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit
Time frame: Day 1 through Week 28
Percentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1) Through Week 28
OLTP; Normalization of LDH was defined as LDH ≤1.0 × ULN at each visit
Time frame: Baseline (Day 1) through Week 28
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Baseline (Day 1) Through Week 28
OLTP
Time frame: Baseline (Day 1) through Week 28
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Week 4 Through Week 28
OLTP
Time frame: Week 4 through Week 28
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1) Through Week 28
OLTP Breakthrough hemolysis is defined as an increase in LDH with concomitant signs or symptoms associated with hemolysis: • An increase in LDH occurs when: * LDH ≥2 × ULN if pre-treatment LDH is ≤1.5 × ULN or * LDH ≥2 × ULN after initial achievement of LDH ≤1.5 × ULN if pre-treatment LDH is \>1.5 × ULN Signs or symptoms should correspond to those known to be associated with intravascular hemolysis due to Paroxysmal nocturnal hemoglobinuria (PNH) limited to the following: new onset or worsening fatigue, headache, dyspnea, hemoglobinuria, abdominal pain, scleral icterus, erectile dysfunction, chest pain, confusion, dysphagia, anemia including hemoglobin value significantly lower (ie, ≥2g/dL decrease) compared to patient's known baseline hemoglobin values, and thrombotic event.
Time frame: Baseline (Day 1) through Week 28
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1) Through Week 28
OLTP Hemoglobin stabilization was defined as participants who did not receive an RBC transfusion and had no decrease in hemoglobin level of ≥2 grams per deciLiter (g/dL).
Time frame: Baseline (Day 1) through Week 28
Change in Hemoglobin Levels From Baseline (Day 1) Through Week 28
OLTP
Time frame: Baseline (Day 1) to Week 28
Percentage of Participants With Transfusion Avoidance From Baseline (Day 1) Through Week 28
OLTP Not requiring a red blood cell (RBC) transfusion as per protocol algorithm
Time frame: Baseline (Day 1) to Week 28
Rate of Red Blood Cells (RBCs) Transfused From Baseline (Day 1) to Week 28
OLTP Rate of RBCs transfused is defined as number of events per person-years of treatment. For each participant, the participant-years are the time from first dose date to week 28 (or early terminations visit if subject discontinued the study early) in the OLTP.
Time frame: Baseline (Day 1) to Week 28
Number of Per-Protocol RBC Units Transfused From Baseline (Day 1) Through Week 28
OLTP
Time frame: Baseline (Day 1) to Week 28
Change in Total Complement Hemolysis Activity Assay (CH50) From Baseline (Day 1) Through Week 28
OLTP
Time frame: Baseline (Day 1) to Week 28
Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1) Through Week 28
OLTP FACIT fatigue is a 13-item scale and for each item 4 is not at all fatigued to 0 very much fatigued. Higher FACIT-Fatigue scores indicate less fatigue (scores range from 0-52). A 5-point change is considered clinically meaningful.
Time frame: Baseline (Day 1) to Week 28
Change in Global Health Status/Quality of Life Scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire Core 30 Items (EORTC QLQ-C30) From Baseline (Day 1) Through Week 28
OLTP EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
Time frame: Baseline (Day 1) to Week 28
Change in Physical Function (PF) Scores on the EORTC QLQ-C30 From Baseline (Day 1) Through Week 28
OLTP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
Time frame: Baseline (Day 1) to Week 28
Concentrations of Total Pozelimab in Serum on Week 28
OLTP
Time frame: On Week 28
Concentrations of Cemdisiran in Plasma on Week 28
OLTP
Time frame: On Week 28
Concentrations of Total C5 on Week 28
OLTP
Time frame: On Week 28
Number of Participants With Pozelimab Anti-Drug Antibody (ADA) Responses Over Time
OLTP and OLEP
Time frame: Up to Week 52 (OLTP [ Week 0 - Week 28] + OLEP [Week 28 - Week 52])
Number of Participants With Cemdisiran Anti-Drug Antibody (ADA) Responses Over Time
OLTP and OLEP
Time frame: Up to Week 52 (OLTP [ Week 0 - Week 28] + OLEP [Week 28 - Week 52])
Percentage of Participants With TEAEs for Participants Who Received Treatment Intensification
OLTP No participants received dose intensification during the study; Therefore, assessment of the safety of pozelimab + cemdisiran combination therapy in participants requiring dose intensification was not conducted.
Time frame: Through Week 28
Change of LDH From Baseline (Day 1e) to Week 24e
Optional Open-Label Extension Period (OLEP)
Time frame: Baseline (Day 1e) to Week 24e
Percent Change of LDH From OLEP Baseline (Day 1e) to Week 24e
OLEP; Percentage of change for units per liter (U/L)
Time frame: Baseline (Day 1e) to Week 24e
Change of LDH From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Percent Change of LDH From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 24e
OLEP
Time frame: Baseline (Day 1e) through Week 24e
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 52e
OLEP
Time frame: Baseline (Day 1e) through Week 52e
Percentage of Participants With Adequate Control of Hemolysis at Each Visit From Baseline (Day 1e) Through Week 52e
OLEP Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit
Time frame: Baseline (Day 1e) through Week 52e
Percentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1e) Through Week 52e
OLEP
Time frame: Baseline (Day 1e) through week 52e
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLEP Baseline (Day 1e) Through Week 52e
OLEP
Time frame: Baseline (Day 1e) through Week 52e
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 24e
OLEP
Time frame: Baseline (Day 1e) through Week 24e
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 52e
OLEP
Time frame: Baseline (Day 1e) through Week 52e
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 24e
OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels
Time frame: Baseline (Day 1e) through Week 24e
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 52e
OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels
Time frame: Baseline (Day 1e) through Week 52e
Change in Hemoglobin Levels From Baseline (Day 1e) to Week 24e
OLEP
Time frame: Baseline (Day 1e) to Week 24e
Change in Hemoglobin Levels From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 24e
OLEP Not requiring a RBC transfusion as per protocol algorithm
Time frame: Baseline (Day 1e) through Week 24e
Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 52e
OLEP Not requiring a RBC transfusion as per protocol algorithm
Time frame: Baseline (Day 1e) to Week 52e
Rate of RBCs Transfused From Baseline (Day 1e) to Week 24e
OLEP
Time frame: Baseline (Day 1e) to Week 24e
Rate of RBCs Transfused From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 24e
OLEP
Time frame: Baseline (Day 1e) to Week 24e
Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Change in CH50 From Baseline (Day 1e) to Week 16e
OLEP
Time frame: Baseline (Day 1e) to Week 16e
Change in CH50 From Baseline (Day 1e) to Week 24e
OLEP
Time frame: Baseline (Day 1e) to Week 24e
Change in CH50 From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Percent Change in CH50 From Baseline (Day 1e) to Week 16e
OLEP
Time frame: Baseline (Day 1e) to Week 16e
Percent Change in CH50 From Baseline (Day 1e) to Week 24e
OLEP
Time frame: Baseline (Day 1e) to Week 24e
Percent Change in CH50 From Baseline (Day 1e) to Week 52e
OLEP
Time frame: Baseline (Day 1e) to Week 52e
Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1e) to Week 52e
OLEP; The FACIT-Fatigue is a 13-item, self-administered assessment of an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-Fatigue items are measured with a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating less fatigue. A 5-point change is considered clinically meaningful.
Time frame: Baseline (Day 1e) to Week 52e
Change in GHS/QoL on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e
OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
Time frame: Baseline (Day 1e) to Week 52e
Change in PF Scores on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e
OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
Time frame: Baseline (Day 1e) to Week 52e
Percentage of Participants With TEAEs Up to Week 52
OLEP
Time frame: Up to Week 52
Concentrations of Total Pozelimab in Serum on Week 52
OLEP
Time frame: On Week 52
Concentrations of Total C5 on Week 52
OLEP
Time frame: On Week 52
Concentrations of Cemdisiran in Plasma on Week 52
OLEP
Time frame: On Week 52
| Milestone | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Started | 12 | 12 |
| Completed | 10 | 12 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Open Label Treatment Period (OLTP)
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Participants with any TEAE | 66.7 | 41.7 |
| Participants with serious TEAE | 16.7 | 0 |
| Participants with severe TEAE | 16.7 | 0 |
OLTP Pre-treatment (mean of LDH values prior to combination dosing); End-of-treatment (mean of LDH value at week 24- through week 28); percentage of change in Upper Limit of Normal (xULN).
| Percentage of change | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Percent Change of Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period | 2.93 ± 36.575 | 3.65 ± 13.608 |
OLTP Adequate control of hemolysis is defined as LDH values ≤1.5 × Upper limit of normal (ULN) from baseline (day 1) to week 28
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1) Through Week 28 | 75.0 | 91.7 |
OLTP
| Percentage of Participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Percentage of Participants Maintaining Adequate Control of Hemolysis From Week 4 Through Week 28 | 83.3 | 91.7 |
OLTP; Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Baseline Visit (Day 1) | 100.0 | 100.0 |
| Pre-treatment | 100.0 | 100.0 |
| Week 1 | 100.0 | 100.0 |
| Week 2 | 100.0 | 100.0 |
| Week 4 | 83.0 | 100.0 |
| Week 6 | 92.0 | 100.0 |
| Week 8 | 100.0 | 100.0 |
| Week 10 | 100.0 | 100.0 |
| Week 12 | 100.0 | 92.0 |
| Week 16 | 100.0 | 100.0 |
| Week 20 | 100.0 | 100.0 |
| Week 24 | 100.0 | 100.0 |
| Week 28 | 92.0 | 100.0 |
OLTP; Normalization of LDH was defined as LDH ≤1.0 × ULN at each visit
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Baseline (Day 1) | 92.0 | 75.0 |
| Pre-treatment | 92.0 | 83.0 |
| Week 1 | 100.0 | 92.0 |
| Week 2 | 92.0 | 83.0 |
| Week 4 | 83.0 | 83.0 |
| Week 6 | 83.0 | 75.0 |
| Week 8 | 100.0 | 82.0 |
| Week 10 | 100.0 | 83.0 |
| Week 12 | 92.0 | 83.0 |
| Week 16 | 92.0 | 75.0 |
| Week 20 | 100.0 | 92.0 |
| Week 24 | 100.0 | 92.0 |
| Week 28 | 83.0 | 83.0 |
OLTP
| Units per Liter (U/L) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Baseline (Day 1) Through Week 28 | 238.18 ± 44.006 | 244.42 ± 39.085 |
OLTP
| U/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Week 4 Through Week 28 | 202.49 ± 38.272 | 211.28 ± 34.280 |
OLTP Breakthrough hemolysis is defined as an increase in LDH with concomitant signs or symptoms associated with hemolysis: • An increase in LDH occurs when: * LDH ≥2 × ULN if pre-treatment LDH is ≤1.5 × ULN or * LDH ≥2 × ULN after initial achievement of LDH ≤1.5 × ULN if pre-treatment LDH is \>1.5 × ULN Signs or symptoms should correspond to those known to be associated with intravascular hemolysis due to Paroxysmal nocturnal hemoglobinuria (PNH) limited to the following: new onset or worsening fatigue, headache, dyspnea, hemoglobinuria, abdominal pain, scleral icterus, erectile dysfunction, chest pain, confusion, dysphagia, anemia including hemoglobin value significantly lower (ie, ≥2g/dL decrease) compared to patient's known baseline hemoglobin values, and thrombotic event.
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1) Through Week 28 | 8.3 | 0.0 |
OLTP Hemoglobin stabilization was defined as participants who did not receive an RBC transfusion and had no decrease in hemoglobin level of ≥2 grams per deciLiter (g/dL).
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1) Through Week 28 | 75.0 | 91.7 |
OLTP
| grams per Liter (g/L) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Change in Hemoglobin Levels From Baseline (Day 1) Through Week 28 | -1.3 ± 13.77 | 10.3 ± 7.41 |
OLTP Not requiring a red blood cell (RBC) transfusion as per protocol algorithm
| Percentage of participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Percentage of Participants With Transfusion Avoidance From Baseline (Day 1) Through Week 28 | 83.3 | 100.0 |
OLTP Rate of RBCs transfused is defined as number of events per person-years of treatment. For each participant, the participant-years are the time from first dose date to week 28 (or early terminations visit if subject discontinued the study early) in the OLTP.
| Events per person-years of treatment | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Rate of Red Blood Cells (RBCs) Transfused From Baseline (Day 1) to Week 28 | 1.284 (0.169 to 9.760) | NA (NA to NA) |
OLTP
| Units | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Number of Per-Protocol RBC Units Transfused From Baseline (Day 1) Through Week 28 | 1.5 ± 3.73 | 0.0 ± 0.00 |
OLTP
| Units per milliliter (U/mL) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Change in Total Complement Hemolysis Activity Assay (CH50) From Baseline (Day 1) Through Week 28 | 0.0 ± 0.0 | -0.1 ± 0.29 |
OLTP FACIT fatigue is a 13-item scale and for each item 4 is not at all fatigued to 0 very much fatigued. Higher FACIT-Fatigue scores indicate less fatigue (scores range from 0-52). A 5-point change is considered clinically meaningful.
| Score on a scale | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1) Through Week 28 | -6.0 ± 10.09 | -2.0 ± 4.36 |
OLTP EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
| Score on a scale | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Change in Global Health Status/Quality of Life Scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire Core 30 Items (EORTC QLQ-C30) From Baseline (Day 1) Through Week 28 | -9.4 ± 23.33 | -1.9 ± 13.03 |
OLTP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
| Score on a scale | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Change in Physical Function (PF) Scores on the EORTC QLQ-C30 From Baseline (Day 1) Through Week 28 | -6.7 ± 19.19 | 0.7 ± 9.09 |
OLTP
| mg/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Concentrations of Total Pozelimab in Serum on Week 28 | 131 ± 74.8 | 58.2 ± 31.5 |
OLTP
| mg/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Concentrations of Cemdisiran in Plasma on Week 28 | NA ± NA | NA ± NA |
OLTP
| mg/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Concentrations of Total C5 on Week 28 | 0 (0 to 13.8) | 0 (0 to 0) |
OLTP and OLEP
| Participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Treatment-Boosted Response | 0 | 0 |
| Treatment-Emergent Response | 0 | 0 |
OLTP and OLEP
| Participants | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Treatment-Boosted Response | 0 | 0 |
| Treatment-Emergent Response | 0 | 1 |
OLTP No participants received dose intensification during the study; Therefore, assessment of the safety of pozelimab + cemdisiran combination therapy in participants requiring dose intensification was not conducted.
No measurements were reported for this outcome.
Optional Open-Label Extension Period (OLEP)
| U/L | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change of LDH From Baseline (Day 1e) to Week 24e | -18.2 ± 108.40 |
OLEP; Percentage of change for units per liter (U/L)
| Percentage of change | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percent Change of LDH From OLEP Baseline (Day 1e) to Week 24e | -0.7 ± 20.60 |
OLEP
| U/L | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change of LDH From Baseline (Day 1e) to Week 52e | -14.5 ± 105.90 |
OLEP
| Percentage of change | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percent Change of LDH From Baseline (Day 1e) to Week 52e | 0.2 ± 19.49 |
OLEP
| Percentage of Participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 24e | 95.7 |
OLEP
| Percentage of Participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 52e | 95.7 |
OLEP Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit
| Percentage of participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| OLEP Baseline (Day 1e) | 96.0 |
| Week 8e | 100.0 |
| Week 16e | 100.0 |
| Week 24e | 100.0 |
| Week 32e | 100.0 |
| Week 40e | 100.0 |
| Week 52e | 100.0 |
OLEP
| Percentage of participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| OLEP Baseline (Day 1e) | 87.0 |
| Week 8e | 83.0 |
| Week 16e | 82.0 |
| Week 24e | 82.0 |
| Week 32e | 86.0 |
| Week 40e | 82.0 |
| Week 52e | 82.0 |
OLEP
| U/L | Pozelimab Q4W + Cemdisiran |
|---|---|
| Average LDH (U/L) Based on Area Under the Curve (AUC) From OLEP Baseline (Day 1e) Through Week 52e | 154.63 ± 38.231 |
OLEP
| Percentage of Participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 24e | 4.3 |
OLEP
| Percentage of participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 52e | 4.3 |
OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels
| Percentage of participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 24e | 78.3 |
OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels
| Percentage of participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 52e | 69.6 |
OLEP
| g/L | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in Hemoglobin Levels From Baseline (Day 1e) to Week 24e | 0.8 ± 15.63 |
OLEP
| g/L | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in Hemoglobin Levels From Baseline (Day 1e) to Week 52e | -0.6 ± 12.60 |
OLEP Not requiring a RBC transfusion as per protocol algorithm
| Percentage of Participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 24e | 87.0 |
OLEP Not requiring a RBC transfusion as per protocol algorithm
| Percentage of Participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 52e | 87.0 |
OLEP
| Events per person-years of treatment | Pozelimab Q4W + Cemdisiran |
|---|---|
| Rate of RBCs Transfused From Baseline (Day 1e) to Week 24e | 0.591 (0.143 to 2.445) |
OLEP
| Events per person-years of treatment | Pozelimab Q4W + Cemdisiran |
|---|---|
| Rate of RBCs Transfused From Baseline (Day 1e) to Week 52e | 0.506 (0.092 to 2.773) |
OLEP
| Units | Pozelimab Q4W + Cemdisiran |
|---|---|
| Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 24e | 0.4 ± 1.47 |
OLEP
| Units | Pozelimab Q4W + Cemdisiran |
|---|---|
| Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 52e | 0.9 ± 3.95 |
OLEP
| U/mL | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in CH50 From Baseline (Day 1e) to Week 16e | 0.0 ± 0.00 |
OLEP
No measurements were reported for this outcome.
OLEP
| U/mL | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in CH50 From Baseline (Day 1e) to Week 52e | 0.0 ± 0.21 |
OLEP
| Percentage of change | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percent Change in CH50 From Baseline (Day 1e) to Week 16e | NA |
OLEP
| Percentage of change | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percent Change in CH50 From Baseline (Day 1e) to Week 24e | NA |
OLEP
| Percentage of change | Pozelimab Q4W + Cemdisiran |
|---|---|
| Percent Change in CH50 From Baseline (Day 1e) to Week 52e | NA |
OLEP; The FACIT-Fatigue is a 13-item, self-administered assessment of an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-Fatigue items are measured with a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating less fatigue. A 5-point change is considered clinically meaningful.
| Score on a scale | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1e) to Week 52e | -0.9 ± 5.95 |
OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
| Score on a scale | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in GHS/QoL on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e | 6.0 ± 13.73 |
OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
| Score on a scale | Pozelimab Q4W + Cemdisiran |
|---|---|
| Change in PF Scores on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e | -0.3 ± 3.93 |
OLEP
| Percentage of participants | Pozelimab Q4W + Cemdisiran |
|---|---|
| Participants with any TEAE | 73.9 |
| Participants with serious TEAE | 8.7 |
| Participants with severe TEAE | 4.3 |
OLEP
| mg/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Concentrations of Total Pozelimab in Serum on Week 52 | 63.4 ± 35.6 | 58.6 ± 28.7 |
OLEP
| mg/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Concentrations of Total C5 on Week 52 | 0 (0 to 8.05) | NA (NA to NA) |
OLEP
| mg/L | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran |
|---|---|---|
| Concentrations of Cemdisiran in Plasma on Week 52 | NA ± NA | NA ± NA |
Collected over From first dose up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OLTP_Pozelimab Q2W + Cemdisiran | 0/12 (0%) | 3/12 (25%) | 8/12 (66.7%) |
| OLTP_Pozelimab Q4W + Cemdisiran | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| OLEP_Pozelimab Q4W + Cemdisiran | 0/23 (0%) | 2/23 (8.7%) | 10/23 (43.5%) |
| Event | OLTP_Pozelimab Q2W + Cemdisiran | OLTP_Pozelimab Q4W + Cemdisiran | OLEP_Pozelimab Q4W + Cemdisiran |
|---|---|---|---|
| COVID-19Infections and infestations | 1/12 | 0/12 | 0/23 |
| GastroenteritisInfections and infestations | 1/12 | 0/12 | 0/23 |
| Upper respiratory tract infectionInfections and infestations | 1/12 | 0/12 | 0/23 |
| HaemolysisBlood and lymphatic system disorders | 0/12 | 0/12 | 1/23 |
| Anal fistulaGastrointestinal disorders | 0/12 | 0/12 | 1/23 |
| Large intestine polypGastrointestinal disorders | 0/12 | 0/12 | 1/23 |
| Event | OLTP_Pozelimab Q2W + Cemdisiran | OLTP_Pozelimab Q4W + Cemdisiran | OLEP_Pozelimab Q4W + Cemdisiran |
|---|---|---|---|
| COVID-19Infections and infestations | 2/12 | 1/12 | 4/23 |
| Upper respiratory tract infectionInfections and infestations | 2/12 | 0/12 | 4/23 |
| Injection site reactionGeneral disorders | 2/12 | 2/12 | 3/23 |
| Chest painGeneral disorders | 0/12 | 1/12 | 0/23 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 0/23 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 0/23 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/12 | 1/12 | 0/23 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/12 | 0/12 | 0/23 |
| Abdominal painGastrointestinal disorders | 0/12 | 1/12 | 0/23 |
| Anal fistulaGastrointestinal disorders | 1/12 | 0/12 | 0/23 |
| Age, Continuous(Years) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran | Total |
|---|---|---|---|
| Mean | 41.4 ± 16.89 | 53.2 ± 16.38 | 47.3 ± 17.34 |
| Sex: Female, Male(Participants) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 7 | 6 | 13 |
| Race/Ethnicity, Customized(Participants) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 12 | 24 |
| Race/Ethnicity, Customized(Participants) | Pozelimab Q2W + Cemdisiran | Pozelimab Q4W + Cemdisiran | Total |
|---|---|---|---|
| White | 1 | 1 | 2 |
| Black or African American | 0 | 0 | 0 |
| Asian | 10 | 11 | 21 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Jul 2021 to primary completion in Oct 2022, 14 months.
Results were first posted in Jan 2025, 2 years 2 months after primary completion. A results delay was requested in Oct 2023.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 14 months is below that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pozelimab · Cemdisiran